L
LIFECORE BIOMEDICAL INC.
NASDAQ: LFCR (Lifecore Biomedical, Inc.)
Last update: 8 hours ago4.46
0.00 (0.00%)
| Previous Close | 4.46 |
| Volume | 280,839 |
| Price / Earnings (Forward) | 8.67 |
| Price / Sales | 1.20 |
| Price / Book | 197.99 |
| 52 Weeks Range |
| Profit Margin | -34.27% |
| Operating Margin (TTM) | -6.52% |
| Diluted EPS (TTM) | -1.47 |
| Quarterly Revenue Growth (YOY) | -1.50% |
| Total Debt/Equity (MRQ) | 274.83% |
| Current Ratio (MRQ) | 2.71 |
| Operating Cash Flow (TTM) | 2.69 M |
| Levered Free Cash Flow (TTM) | -27.28 M |
| Return on Assets (TTM) | -3.11% |
| Return on Equity (TTM) | -83.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Lifecore Biomedical, Inc. | Mixed | Mixed |
AIStockmoo Score
0.2
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.17 |
|
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 2.06% |
| % Held by Institutions | 72.40% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Wynnefield Capital Inc | 30 Jun 2026 | 4,703,216 |
| Legion Partners Asset Management, Llc | 30 Jun 2026 | 4,461,823 |
| Greenhaven Road Investment Management, L.P. | 30 Jun 2026 | 3,190,769 |
| Quinn Opportunity Partners Llc | 30 Jun 2026 | 453,495 |
| Dcf Advisers, Llc | 30 Jun 2026 | 424,500 |
| Wittenberg Investment Management, Inc. | 30 Jun 2026 | 314,015 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |